Metabolic Disturbances Identified in Plasma Samples from ST-Segment Elevation Myocardial Infarction Patients

Related Experiment Video

Updated: Jan 21, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

Vânia Aparecida Mendes Goulart1, Anderson Kenedy Santos1, Valéria Cristina Sandrim2

  • 1Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

Disease Markers
|July 30, 2019
PubMed

Insights

This study identified novel plasma biomarkers for ST-segment elevation myocardial infarction (STEMI). Metabolomic analysis revealed significant alterations in lipids and amines, offering new diagnostic signatures for this severe heart condition.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Metabolomics

Background:

  • ST-segment elevation myocardial infarction (STEMI) is a critical condition leading to significant global mortality.
  • STEMI results from coronary artery occlusion, causing heart damage and altering the heart's metabolic profile.
  • Identifying novel biomarkers is crucial for improving STEMI diagnosis and patient outcomes.

Purpose of the Study:

  • To identify novel plasma biomarkers and metabolic signatures associated with STEMI.
  • To characterize the metabolic phenotype of STEMI patients compared to healthy individuals.

Main Methods:

  • Phenotypic characterization of 15 STEMI patients and 19 healthy controls.
  • Target metabolomics analysis of plasma samples using UPLC-MS/MS and FIA-MS.
  • Multivariate analysis to identify metabolic alterations.

Main Results:

  • Significant alterations in phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, and biogenic amines were observed in STEMI patients.
  • Multivariate analysis indicated changes in glycerophospholipid, alpha-linolenic acid, and sphingolipid metabolisms.
  • These metabolic changes represent a potential biosignature for heart dysfunction in STEMI.

Conclusions:

  • Plasma metabolomic profiling can identify distinct metabolic signatures in STEMI.
  • Alterations in specific lipid and amine concentrations may serve as novel biomarkers for STEMI diagnosis.
  • Further research into these metabolic pathways could lead to improved diagnostic and therapeutic strategies for STEMI.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.7K
Acute Myocardial Infarction in Rats07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

54.5K

Related Concept Videos

Ecological Disturbance02:26

Ecological Disturbance

An ecological disturbance is a temporary disruption in the environment resulting from abiotic, biotic, or anthropogenic factors, causing a pronounced change in an ecosystem. The impact of an ecological disturbance, which can depend on its intensity, frequency, and spatial distribution, plays a significant role in shaping the species diversity within the ecosystem.
20.7K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
39.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
2.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
199
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175